TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT04256018

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is studying Mogamulizumab and LD TSEBT for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Mogamulizumab (DRUG): Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle. | LD TSEBT (RADIATION): Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks

Drugs / treatments
Mogamulizumab, LD TSEBT
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

NCT04256018

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is studying Mogamulizumab and LD TSEBT for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Must be well enough for treatment (adequate performance status)

What's being tested

Mogamulizumab (DRUG): Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle. | LD TSEBT (RADIATION): Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks

Drugs / treatments: Mogamulizumab, LD TSEBT

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 30 patients

Primary endpoint: Overall response rate (ORR)

Ages: 18 Years to —

Start date: 2020-03-30 | Est. completion: 2026-12

Locations

1 US sites · 1 total

California

Contact

Zainab Ahmed | zahmed01@stanford.edu | 650-387-4436

Sponsor: Stanford University (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04256018

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.